Search

Emricasan

Emricasan is the first caspase inhibitor tested in human which has received orphan drug status by FDA. … It is developed by Pfizer and made in such a way that it protects liver cells from excessive apoptosis.

Difluocortolone

It is commonly used in dermatology for the reduction of inflammation and itching. It was submitted to the FDA in July 1984 by the pharmaceutical company Schering AG.[L1082]

Irsogladine

Irsogladine is under investigation in clinical trial NCT02581696 (The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers).

Methyl red

NP-50301

The majority of sufferers of DES are postmenopausal women; and clinical research around the world has suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.

OPC-14523

OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.

Indecainide

Indecainide is a rarely used antidysrhythmic. Indecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of...

Camostat

[A193842,A193848] It was first described in the literature in 1981, as part of research on the inhibition of skin tumors in mice. … [A198771,A198777,A193800] Camostat mesylate was first approved in Japan in January 2006.[L13197]

Suramin

A polyanionic compound with an unknown mechanism of action. … Suramin is manufactured by Bayer in Germany as Germanin®.

Linsitinib

An orally bioavailable small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with potential antineoplastic activity. … IGF-1R inhibitor OSI-906 selectively inhibits IGF-1R, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell apoptosis.